These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36407498)

  • 21. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation.
    Kumar R; Singh B; Bakshi G; Katare OP
    Pharm Dev Technol; 2007; 12(6):591-601. PubMed ID: 18161632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability enhancement of voriconazole using liposomal pastilles: Formulation and experimental design investigation.
    Lankalapalli S; Vemuri VD; Tenneti VSVK; Guntaka PR
    J Liposome Res; 2022 Sep; 32(3):293-307. PubMed ID: 34923884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulation and Evaluation of Liposomes for Transdermal Delivery of Celecoxib.
    Moghimipour E; Salami A; Monjezi M
    Jundishapur J Nat Pharm Prod; 2015 Feb; 10(1):e17653. PubMed ID: 27747190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
    Dadashzadeh S; Vali AM; Rezaie M
    Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulation design and optimization of cationic-charged liposomes of brimonidine tartrate for effective ocular drug delivery by design of experiment (DoE) approach.
    Soni PK; Saini TR
    Drug Dev Ind Pharm; 2021 Nov; 47(11):1847-1866. PubMed ID: 35484943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of liposome formulation parameters and their influence on encapsulation, stability and drug release in glibenclamide liposomes.
    Maritim S; Boulas P; Lin Y
    Int J Pharm; 2021 Jan; 592():120051. PubMed ID: 33161039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
    Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
    J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH.
    Nahar K; Rashid J; Absar S; Al-Saikhan FI; Ahsan F
    Pharm Res; 2016 Jul; 33(7):1696-710. PubMed ID: 27048347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development, characterization and in vivo evaluation of benzocaine-loaded liposomes.
    Mura P; Maestrelli F; González-Rodríguez ML; Michelacci I; Ghelardini C; Rabasco AM
    Eur J Pharm Biopharm; 2007 Aug; 67(1):86-95. PubMed ID: 17350813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of critical process parameters and critical material attributes on the critical quality attributes of liposomal formulations prepared using continuous processing.
    Yenduri G; Costa AP; Xu X; Burgess DJ
    Int J Pharm; 2022 May; 619():121700. PubMed ID: 35358645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.
    Gabizon A; Ohana P; Amitay Y; Gorin J; Tzemach D; Mak L; Shmeeda H
    Cancer Drug Resist; 2021; 4(2):463-484. PubMed ID: 35582027
    [No Abstract]   [Full Text] [Related]  

  • 33. Development and characterization of minoxidil-loaded liposomal system for delivery to pilosebaceous units.
    Jain B; Singh B; Katare OP; Vyas SP
    J Liposome Res; 2010 Jun; 20(2):105-14. PubMed ID: 19698000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicochemical characterization and skin permeation of liposome formulations containing clindamycin phosphate.
    Shanmugam S; Song CK; Nagayya-Sriraman S; Baskaran R; Yong CS; Choi HG; Kim DD; Woo JS; Yoo BK
    Arch Pharm Res; 2009 Jul; 32(7):1067-75. PubMed ID: 19641889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of thermosensitive liposomal formulations on loading and release of high molecular weight biomolecules.
    Huang X; Li M; Bruni R; Messa P; Cellesi F
    Int J Pharm; 2017 May; 524(1-2):279-289. PubMed ID: 28377318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
    Padamwar MN; Pokharkar VB
    Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal gels for site-specific, sustained delivery of celecoxib: in vitro and in vivo evaluation.
    Fetih G; Fathalla D; El-Badry M
    Drug Dev Res; 2014 Jun; 75(4):257-66. PubMed ID: 24939834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity.
    Zhang B; Kopper TJ; Liu X; Cui Z; Van Lanen SG; Gensel JC
    CNS Neurosci Ther; 2019 May; 25(5):591-600. PubMed ID: 30677254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.